Next Article in Journal
Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer
Next Article in Special Issue
Vectored-Vaccine Platforms Enabled Rapid Development of Safe and Effective Vaccines in Response to COVID-19 Pandemic Situation
Previous Article in Journal
Construction and Immunogenicity of Modified mRNA-Vaccine Variants Encoding Influenza Virus Antigens
Previous Article in Special Issue
The Safe Baculovirus-Based PrM/E DNA Vaccine Protected Fetuses against Zika Virus in A129 Mice
Review

Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2

Sciensano, Service Biosafety and Biotechnology, Rue Juliette Wytsmanstraat 14, B-1050 Brussels, Belgium
*
Author to whom correspondence should be addressed.
Academic Editors: Amine A. Kamen and Olivier Henry
Vaccines 2021, 9(5), 453; https://doi.org/10.3390/vaccines9050453
Received: 31 March 2021 / Revised: 23 April 2021 / Accepted: 1 May 2021 / Published: 3 May 2021
(This article belongs to the Special Issue Vectored Vaccines)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. Over the past months, considerable efforts have been put into developing effective and safe drugs and vaccines against SARS-CoV-2. Various platforms are being used for the development of COVID-19 vaccine candidates: recombinant viral vectors, protein-based vaccines, nucleic acid-based vaccines, and inactivated/attenuated virus. Recombinant viral vector vaccine candidates represent a significant part of those vaccine candidates in clinical development, with two already authorised for use in the European Union and one currently under rolling review by the European Medicines Agency (EMA). Since recombinant viral vector vaccine candidates are considered as genetically modified organisms (GMOs), their regulatory oversight includes besides an assessment of their quality, safety and efficacy, also an environmental risk assessment (ERA). The present article highlights the main characteristics of recombinant viral vector vaccine (candidates) against SARS-CoV-2 in the pipeline and discusses their features from an environmental risk point of view. View Full-Text
Keywords: SARS-CoV-2; COVID-19; recombinant viral vector vaccines; environmental risk assessment; vaccination; biosafety SARS-CoV-2; COVID-19; recombinant viral vector vaccines; environmental risk assessment; vaccination; biosafety
MDPI and ACS Style

Baldo, A.; Leunda, A.; Willemarck, N.; Pauwels, K. Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2. Vaccines 2021, 9, 453. https://doi.org/10.3390/vaccines9050453

AMA Style

Baldo A, Leunda A, Willemarck N, Pauwels K. Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2. Vaccines. 2021; 9(5):453. https://doi.org/10.3390/vaccines9050453

Chicago/Turabian Style

Baldo, Aline, Amaya Leunda, Nicolas Willemarck, and Katia Pauwels. 2021. "Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2" Vaccines 9, no. 5: 453. https://doi.org/10.3390/vaccines9050453

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop